Review
Health Care Sciences & Services
Mark N. Pernik, Cylaina E. Bird, Jeffrey Traylor, Diana D. Shi, Timothy E. Richardson, Samuel K. McBrayer, Kalil G. Abdullah
Summary: The emergence of patient-derived cancer organoid (PDO) models, which closely recapitulate parental tumor tissue, provides a promising approach in cancer research. PDOs can efficiently retain tumor-specific properties and enhance precision oncologic care for patients compared to traditional cell lines and xenograft models. This review highlights the advantages of PDOs in cancer modeling and potential clinical applications.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Yajing Liu, Yanbing Zhou, Pu Chen
Summary: Lung cancer is a highly prevalent and deadly malignancy that requires personalized treatment strategies. Lung cancer organoids (LCOs) have the potential to faithfully replicate tumor characteristics and heterogeneity, providing a promising platform for anti-tumor drug discovery. Additionally, LCOs can enhance current precision medicine for lung cancer and overcome the limitations of current approaches.
FRONTIERS IN ONCOLOGY
(2023)
Review
Chemistry, Physical
Lanxiang Huang, Yaqi Xu, Na Wang, Kezhen Yi, Xiaodan Xi, Huaqi Si, Qian Zhang, Ming Xiang, Yuan Rong, Yufeng Yuan, Fubing Wang
Summary: This article discusses the advantages and applications of patient-derived tumor organoids and highlights the biological functions of circulating tumor cells. It also provides an overview of the latest advancements in research on circulating tumor cell-derived organoids and discusses the potential applications and challenges of this technology.
Review
Oncology
Mikaela Gronholm, Michaela Feodoroff, Gabriella Antignani, Beatriz Martins, Firas Hamdan, Vincenzo Cerullo
Summary: Cancer immunotherapy has transformed tumor treatment, but there is a lack of efficient testing platforms for pretreatment evaluation of therapies and understanding the tumor microenvironment. Patient-derived tumor organoid cultures and complex immune-organoid cultures offer potential for preclinical testing platforms in precision cancer immunotherapy.
Review
Cell Biology
Huihui Li, Zexin Chen, Ning Chen, Yun Fan, Yaping Xu, Xiaoling Xu
Summary: Lung cancer, as the leading cause of cancer-related mortality, remains a global threat to human health. Despite progress in research and treatment, there is an urgent need for reliable preclinical models and therapeutic approaches. Patient-derived organoids have emerged as a promising model for high-throughput drug screening and guidance for lung cancer treatment.
CELL COMMUNICATION AND SIGNALING
(2023)
Review
Biochemistry & Molecular Biology
Evangelia Sereti, Irida Papapostolou, Konstantinos Dimas
Summary: Despite its aggression and resistance to treatment, pancreatic ductal adenocarcinoma (PDAC) can potentially benefit from the development of organoid culture systems. These PDAC organoids have the potential to bridge the gap between in vitro and in vivo models, making them powerful preclinical tools for studying the biology, progression, and treatment response of pancreatic cancer. This review highlights the importance of PDAC organoids in advancing precision medicine for this deadly malignancy.
Article
Cell Biology
Shuyi Ji, Li Feng, Zile Fu, Gaohua Wu, Yingcheng Wu, Youpei Lin, Dayun Lu, Yuanli Song, Peng Cui, Zijian Yang, Chen Sang, Guohe Song, Shangli Cai, Yuanchuang Li, Hanqing Lin, Shu Zhang, Xiaoying Wang, Shuangjian Qiu, Xiaoming Zhang, Guoqiang Hua, Junqiang Li, Jian Zhou, Zhi Dai, Xiangdong Wang, Li Ding, Pei Wang, Daming Gao, Bing Zhang, Henry Rodriguez, Jia Fan, Hans Clevers, Hu Zhou, Yidi Sun, Qiang Gao
Summary: We established a patient-derived liver cancer organoid biobank (LICOB) that comprehensively represents the histological and molecular characteristics of various liver cancer types. Through high-throughput drug screening and integrative analysis, we identified molecular features associated with drug responses and predicted potential drug combinations for personalized patient treatment. The synergistic inhibition effect of mTOR inhibitor temsirolimus and the multitargeted tyrosine kinase inhibitor lenvatinib was validated in organoids and patient-derived xenografts models. We also provide a user-friendly web portal to serve the biomedical research community.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Vittoria Rago, Anna Perri, Silvia Di Agostino
Summary: One of the major goals in cancer research is to develop new anticancer therapies. Preclinical in vitro models, such as patient-derived xenograft (PDX) models and cultured organoids derived from patients (PDO), have become indispensable tools for understanding cancer progression, drug resistance, and metastasis. This article reviews studies from the past 10 years on the use of PDX models and PDOs in studying prostate cancer, which is characterized by genomic instability and resistance to conventional therapies. The limitations and new challenges in using these models for drug testing and developing molecular therapies are also discussed.
Review
Oncology
Dandan Guan, Xiaozhen Liu, Qingyang Shi, Bangjie He, Chaopeng Zheng, Xuli Meng
Summary: Immunotherapy is gaining attention as a treatment strategy for breast cancer. However, precise application of immunotherapy in breast cancer has not been fully studied. This study investigates different organoid culture methods and their applications in modeling the breast cancer tumor microenvironment and precision immunotherapy.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Cell Biology
James Kim, John D. Minna
Summary: In this study, Wang et al. generated 160 human lung cancer organoids from malignant effusions and tested their response to clinically used drugs, aiming to predict patient responses.
CELL REPORTS MEDICINE
(2023)
Article
Oncology
Yurong Song, Travis D. Kerr, Chelsea Sanders, Lisheng Dai, Shaneen S. Baxter, Brandon Somerville, Ryan N. Baugher, Stephanie D. Mellott, Todd B. Young, Heidi E. Lawhorn, Teri M. Plona, Bingfang Xu, Lei Wei, Qiang Hu, Song Liu, Alan Hutson, Baktiar Karim, Sandra Burkett, Simone Difilippantonio, Ligia Pinto, Johannes Gebert, Matthias Kloor, Steven M. Lipkin, Shizuko Sei, Robert H. Shoemaker
Summary: This study established organoids with MSI-H characteristics for studying MMR-deficient cancer biology and developed an orthotopic model suitable for evaluating the efficacy of neoantigen-based vaccines or anticancer drugs.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Hanxiao Xu, Dechao Jiao, Aiguo Liu, Kongming Wu
Summary: Cancer is a life-threatening disease with intratumor heterogeneity. Personalized tumor models capturing individual patients' tumor heterogeneity are urgently needed for precision medicine. Organoid technology, which can generate three-dimensional tissues that accurately recapitulate the characteristics of primary tumors, has shown great potential in accurately modeling cancer. Tumoroids serve as a valuable tool for the discovery of therapeutic targets, prediction of treatment response, and exploration of potential therapies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Bo-Tao Zhang, Jia-Ying Xu, Wei Wang, Yang Zeng, Jun Jiang
Summary: There is increasing evidence suggesting a link between obesity and the occurrence and development of malignant tumors. However, choosing an appropriate animal model is crucial when studying this relationship. Currently used models such as BALB/c nude mice are difficult to induce obesity, while models commonly used for obesity research, such as C57BL/6 mice, are not suitable for tumor xenograft transplantation. This review summarizes several experimental animal models and protocols that can simultaneously induce obesity and tumor xenografts.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Yinxi Zhou, Jinghua Xia, Shuonan Xu, Tao She, Yanning Zhang, Ying Sun, Miaomiao Wen, Tao Jiang, Yanlu Xiong, Jie Lei
Summary: The development and growth of tumors pose a significant and ongoing threat to human life globally. Despite the remarkable progress achieved by advanced therapeutic strategies such as immune checkpoint therapy and CAR-T in treating solid and hematological malignancies, the malignant initiation and progression of cancer remains controversial and requires further research. Experimental animal models not only have great advantages in simulating tumor occurrence, development, and malignant transformation mechanisms, but also can be used to evaluate the therapeutic effects of diverse clinical interventions, gradually becoming indispensable in cancer research. This paper reviews recent research progress in mouse and rat models, focusing on spontaneous, induced, transgenic, and transplantable tumor models, aiming to provide guidance for future studies on malignant mechanisms and tumor prevention.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Zoology
Sergey Karakashev, Ru-Gang Zhang
Summary: Epithelial ovarian cancer is the leading cause of gynecological cancer-related mortality in developed countries, with multiple histological and molecular subtypes. Research focusing on animal models that consider the heterogeneity of the disease is crucial for studying novel therapies.
ZOOLOGICAL RESEARCH
(2021)
Review
Cell Biology
Ramon U. Jin, Jason C. Mills
JOURNAL OF MOLECULAR CELL BIOLOGY
(2020)
Review
Developmental Biology
Lillian B. Spatz, Ramon U. Jin, Jason C. Mills
Summary: In October 2020, the Keystone Symposia Global Health Series held a Keystone eSymposia discussing 'Tissue Plasticity: Preservation and Alteration of Cellular Identity'. The event highlighted cell identity changes in various contexts and emphasized the importance of conserved mechanisms governing plasticity, with autodegradative activity playing a crucial role across different organs and organisms.